According to the LC, the number of HER2 IHC score +2 and +3 cases in IT adenocarcinomas was 107/310 (34%), while the number of cases in DT carcinomas was 16/216 (7%), and statistically, significantly higher expression was observed in IT adenocarcinomas (P < .001) (Figure 2E). The gene discussed is ERBB2; the disease is carcinoma.